QLGN Qualigen Therapeutics, Inc. Stock Quote

QLGN [NASD]

Index	-	P/E	-	EPS (ttm)	-0.61	Insider Own	8.72%	Shs Outstand	31.29M	Perf Week	10.99%
Market Cap	16.55M	Forward P/E	-	EPS next Y	-0.62	Insider Trans	0.00%	Shs Float	25.67M	Perf Month	-23.84%
Income	-17.90M	PEG	-	EPS next Q	-0.17	Inst Own	7.80%	Short Float	4.81%	Perf Quarter	-32.63%
Sales	5.70M	P/S	2.90	EPS this Y	45.60%	Inst Trans	-1.92%	Short Ratio	1.01	Perf Half Y	-52.82%
Book/sh	0.53	P/B	0.95	EPS next Y	-	ROA	-30.80%	Target Price	7.25	Perf Year	-72.57%
Cash/sh	0.53	P/C	0.95	EPS next 5Y	-	ROE	-46.70%	52W Range	0.45 - 3.12	Perf YTD	-52.82%
Dividend	-	P/FCF	-	EPS past 5Y	65.40%	ROI	-136.60%	52W High	-83.82%	Beta	-0.41
Dividend %	-	Quick Ratio	4.30	Sales past 5Y	-	Gross Margin	23.40%	52W Low	12.18%	ATR	0.08
Employees	39	Current Ratio	4.50	Sales Q/Q	36.40%	Oper. Margin	-	RSI (14)	41.32	Volatility	13.01% 9.33%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-150.60%	Profit Margin	-	Rel Volume	0.10	Prev Close	0.50
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 13 BMO	Payout	-	Avg Volume	1.22M	Price	0.50
Recom	2.00	SMA20	-8.27%	SMA50	-17.11%	SMA200	-51.06%	Volume	0	Change	0.00%

May-13-22 06:00AM	Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results GlobeNewswire +7.65%
May-10-22 09:17AM	Qualigen Therapeutics Partner NanoSynex to Present Technology at BioMed Israel GlobeNewswire
May-03-22 02:24PM	Qualigen Takes Stake In NanoSynex To Gain Access To Next-Gen Diagnostic Platform Benzinga
09:17AM	Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex GlobeNewswire
Apr-29-22 09:15AM	Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President GlobeNewswire
Apr-18-22 06:25AM	QLGN: Secures Worldwide Rights to G4-Selective Cancer Therapeutics Zacks Small Cap Research -12.75%
Apr-12-22 10:15AM	Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference GlobeNewswire +52.06%
Apr-05-22 09:15AM	Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack® GlobeNewswire
Apr-01-22 08:00AM	Qualigen Therapeutics, Inc. Reports Year-End 2021 Financial Results GlobeNewswire
Mar-30-22 09:15AM	Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302 GlobeNewswire
Mar-22-22 09:15AM	Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conference GlobeNewswire +8.04%
Mar-15-22 09:15AM	Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS Program GlobeNewswire
Feb-22-22 09:15AM	Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders GlobeNewswire
Feb-15-22 09:15AM	Data from Qualigen Therapeutics Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference GlobeNewswire
Feb-01-22 09:15AM	Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302 GlobeNewswire
Jan-18-22 09:15AM	Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics GlobeNewswire
Dec-14-21 09:18AM	Qualigen Therapeutics Promotes Amy Broidrick to President GlobeNewswire
Dec-01-21 03:25PM	Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering GlobeNewswire
Nov-29-21 03:50PM	QUALIGEN THERAPEUTICS, INC. ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERING GlobeNewswire -7.06%
Nov-22-21 10:23AM	QLGN: Revenues Increase 38% YoY Zacks Small Cap Research +25.62%
07:43AM	Here's Why Qualigen Therapeutics (NASDAQ:QLGN) Must Use Its Cash Wisely Simply Wall St.
Nov-15-21 09:00AM	Qualigen Therapeutics, Inc. Reports Third Quarter 2021 Financial Results GlobeNewswire
Oct-19-21 09:00AM	Peer-Reviewed Article Confirms That Qualigens FastPack® is as Accurate in Thyroid Stimulating Hormone Measurement -- and Much Faster -- Than a Leading Laboratory Method GlobeNewswire
Sep-15-21 07:30AM	Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit GlobeNewswire +5.11%
Sep-08-21 07:30AM	Qualigen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Aug-31-21 06:22AM	QLGN: Focusing on Advancement of QN-247 and RAS-F Zacks Small Cap Research +22.66%
Aug-23-21 09:58AM	4 Penny Stocks Insiders Are Buying Benzinga +7.63%
Aug-17-21 10:01AM	Why Qualigen Therapeutics (QLGN) Stock Plunging After Q2 Update Benzinga -22.16%
08:00AM	Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results GlobeNewswire
07:02AM	25 Stocks Moving in Tuesday's Pre-Market Session Benzinga
Jul-14-21 07:30AM	Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19 GlobeNewswire
Jul-07-21 10:37AM	QLGN: On Track to File IND for QN-165 as COVID-19 Treatment in 2H21 Zacks Small Cap Research +7.85%
Jun-08-21 07:30AM	Qualigen Therapeutics Announces Inclusion in Russell Microcap® Index GlobeNewswire
Jun-02-21 07:30AM	Qualigen Therapeutics, Inc. to Present at the LD Micro Invitational XI Conference GlobeNewswire
May-19-21 07:30AM	Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer GlobeNewswire
May-18-21 02:10PM	Qualigen Therapeutics Inc to Host Earnings Call ACCESSWIRE
May-14-21 01:35PM	Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Apr-26-21 07:00AM	QLGN: IND Filing for QN-165 as COVID-19 Treatment Expected in 2Q21 Zacks Small Cap Research +11.44%
07:00AM	QLGN: IND Filing for QN-165 as COVID-19 Treatment Expected in 2H21 Zacks Small Cap Research
06:28AM	QLGN: IND Filing for QN-165 as COVID-19 Treatment Expected in 2Q21 Zacks Small Cap Research
Apr-19-21 01:16PM	Qualigen Therapeutics Plans to Combat COVID-19 Variants Benzinga
Apr-06-21 09:30AM	Is Qualigen Therapeutics (NASDAQ:QLGN) In A Good Position To Invest In Growth? Simply Wall St.
Mar-18-21 08:30AM	Qualigen Therapeutics, Inc. to present at the Benzinga Biotech Small Cap Conference GlobeNewswire
Mar-09-21 08:30AM	Qualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer Position GlobeNewswire
Mar-08-21 08:30AM	Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference GlobeNewswire +10.07%
Mar-01-21 08:30AM	Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL GlobeNewswire
Jan-26-21 09:00AM	Qualigen Therapeutics Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack® Diagnostics Products in China PR Newswire
Dec-30-20 11:16AM	Insider Buys Qualigen Therapeutics Stock Benzinga
Dec-22-20 09:00AM	Qualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook PR Newswire
Dec-18-20 03:07PM	Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering PR Newswire
Dec-16-20 10:25AM	Qualigen Therapeutics, Inc. Announces $12 Million Registered Direct Offering PR Newswire -10.57%
Dec-15-20 09:00AM	Qualigen Therapeutics Announces Issuance of U.S. Patent for Expanded Applications of ALAN Anticancer Platform Technology PR Newswire +14.97%
Dec-08-20 09:00AM	Qualigen Therapeutics Announces Board Member Amy Broidrick as EVP, Chief Strategy Officer and Names Sidney Emery, Jr. to its Board PR Newswire
Dec-02-20 09:00AM	Qualigen Therapeutics Completes Recertification of Existing AS1411 Drug Supply for Use in Upcoming Clinical Trials PR Newswire
Nov-30-20 09:40AM	QLGN: Testing AS1411 as COVID-19 Treatment Zacks Small Cap Research
Nov-13-20 09:00AM	Qualigen Therapeutics Issues CEO Letter to Stockholders, Reports on Significant Progress and Fiscal Second Quarter Financial Results PR Newswire
Nov-05-20 09:00AM	Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials PR Newswire
Oct-28-20 09:00AM	Qualigen Therapeutics Receives Positive Pre-IND Response from FDA for the Clinical Development of AS1411 as a Treatment for COVID-19 PR Newswire
Oct-08-20 09:00AM	Qualigen Therapeutics Enters into Commercialization Agreement for its FastPack® Diagnostic Products in China PR Newswire
Oct-01-20 09:00AM	Qualigen Therapeutics Expands Research Agreement with University of Louisville for ALAN Cancer Drug Candidate PR Newswire
Sep-21-20 11:53AM	QLGN: Initiating Coverage of Qualigen Therapeutics, Inc.; Targeting Cancer and Infectious Diseases Zacks Small Cap Research +9.00%
Sep-17-20 09:00AM	Qualigen Therapeutics Announces Filing of U.S. Provisional Patent Application for the Use of AS1411 to Prevent Viral Infections PR Newswire
Aug-31-20 09:00AM	Qualigen Therapeutics Engages IRISYS LLC as GMP Manufacturer for AS1411 Drug Product PR Newswire
Aug-28-20 08:00AM	Qualigen Therapeutics Appoints Amy Broidrick to its Board of Directors PR Newswire
Aug-20-20 08:00AM	Qualigen Therapeutics Announces Issuance of STARS Technology Patent by the U.S. Patent and Trademark Office PR Newswire
Aug-14-20 05:24PM	Qualigen Therapeutics Announces Business Highlights and First Quarter Fiscal Year 2021 Financial Results; Has $16 Million in Cash on Hand as of Today PR Newswire
Aug-06-20 03:59PM	Qualigen Therapeutics to Host Business Update Conference Call on August 18, 2020 PR Newswire
Aug-04-20 04:05PM	Qualigen Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire
Aug-02-20 05:32PM	Qualigen Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire
Jul-30-20 08:00AM	Qualigen Therapeutics Begins Shipping FastPack® COVID-19 Antibody Test PR Newswire -7.63%
Jul-22-20 08:00AM	Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville for RAS Interaction Inhibitor Drug Candidates PR Newswire -8.46%
Jul-13-20 08:00AM	Qualigen Therapeutics CEO Issues Letter to Stockholders PR Newswire -5.83%
Jul-10-20 04:05PM	Qualigen Therapeutics, Inc. Announces Closing of $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire
Jul-08-20 05:19PM	Qualigen Therapeutics, Inc. Announces $8 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PR Newswire
Jul-07-20 08:00AM	Qualigen Therapeutics Engages NFL Hall of Famer Mike Haynes as Advisor to the Company and Spokesman for the FastPack® Rapid Diagnostic System "Which Saved My Life" PR Newswire
Jul-01-20 08:00AM	Qualigen Therapeutics Submits Notification to FDA to Commence Distribution of its FastPack® COVID-19 Antibody Test PR Newswire +15.11%
Jun-10-20 08:00AM	Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19 PR Newswire
Jun-04-20 08:00AM	Qualigen Therapeutics Receives U.S. Patent Notice of Allowance for its STARS Technology PR Newswire
Jun-02-20 08:00AM	Qualigen Therapeutics Releases FastPack® SARS-CoV-2 Antibody Diagnostic Test to University of Louisville to Conduct Validation Studies PR Newswire -5.09%
May-26-20 07:00AM	Qualigen Therapeutics Announces Merger Closing PR Newswire -30.36%

Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kruger Kurt H	Director	Aug 19	Buy	1.23	8,000	9,800	18,000	Aug 20 03:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience